Asthma is an inevitable consequence of the Industrial age and is consequently on the rise in the modern world. Growing pollution from the industrial sector and the ever-growing number of vehicles plying the roads is contributing to a widening prevalence of respiratory disease, of which asthma is one of the most common.
As can be expected, the incidence of the disease is the highest in the highly developed regions of the world, due to the higher pollution generally observed in these regions. Increasing travel also increases the risk of asthma for globetrotters. According to the WHO, around 23 million people suffered from asthma around the world in 2011. As a result of the increasing incidence of the disease, the asthma therapeutics market is expected to grow from its 2013 value of US$18.4 billion at a CAGR of 2.4% to be valued at US$21.7 billion by the end of 2020.
What is the Major Growth Driver for the Asthma Therapeutics Market?
The growing trend of personalized treatment is shaping the global asthma therapeutics market. In the current asthma therapeutic scenario, most patients can use the generic medication available for minor symptoms of asthma. However, the unique conditions of some patients render the generic therapeutics useless, usually due to inaction of the product on the root cause in the particular case. This has led to the growth of the trend of personalized medicine and better diversity in the generic therapeutics for asthma
Apart from personalized therapy, the trend of a combination of medicines is also expected to dominate the therapeutic landscape in the coming years. This is extremely helpful for alleviating inflammation of the respiratory tract, which is the primary symptom of asthma.
What are the Products Dominating the Asthma Therapeutics Market at Present?
In the current scenario, the asthma therapeutics market is dominated by various products aimed at managing and suppressing the symptoms of asthma. Inhaled costicosteroids (ICS) are among the major therapeutics in the global market, used both on their own and as part of the ICS/LABA combination therapy. In both applications, ICS are extremely helpful in the maintenance treatment of asthma.
GlaxoSmithKline (GSK), AstraZeneca, and Merck dominate the asthma therapeutics market at present. GSK’s Advair, consisting of salmeterol xinafoate and fluticasone propionate, and Relvar/Breo, consisting of fluticasone furoate and vilanterol trifenatate, are among the leading therapeutics for asthma. AstraZeneca’s Symbicort, consisting of formoterol fumarate and budesonide, and Merck’s Dulera, consisting of formoterol fumarate and mometasone furoate, and Singulair are the other major products in the asthma therapeutics market, along with Xolair from Novartis and Genentech, and Spiriva from Boehringer Ingelheim.
Browse the full Press Release of Asthma Therapeutics Market : http://www.mrrse.com/asthma-therapeutics-market-report
What are the Promising Pipeline Asthma Therapeutics?
Mepolizumab, reslizumab, dupilumab target interleukins (IL) or IL receptors, and lebrikizumab are among the major monoclonal antibodies going strong in the asthma therapeutics pipeline. Not coincidentally, these molecules have been proven to be more effective in personalized asthma medication than generic medication.